69,756 Shares in IQVIA Holdings Inc. $IQV Purchased by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 69,756 shares of the medical research company’s stock, valued at approximately $15,724,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Claret Asset Management Corp raised its stake in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of IQVIA by 6.3% during the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its stake in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the last quarter. Finally, Brookstone Capital Management raised its stake in shares of IQVIA by 2.2% during the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.2%

NYSE:IQV opened at $172.70 on Thursday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market capitalization of $29.31 billion, a price-to-earnings ratio of 21.97, a PEG ratio of 1.67 and a beta of 1.39. The firm has a fifty day simple moving average of $175.95 and a two-hundred day simple moving average of $204.42. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several analyst reports. Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Morgan Stanley set a $240.00 price target on shares of IQVIA in a research note on Wednesday, February 11th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research note on Friday, February 6th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and a consensus target price of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.